Overview

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Status:
Withdrawn

Trial end date:
2029-01-01

Target enrollment:

Participant gender:

Summary

Prospective, multicenter, open label, phase II randomized clinical trial in DLBCL patients relapsed or refractory to first line R-chemo, aged 18-70 years and candidate to autologous transplant. Patients will be randomized 1:1 to received 4 cycles of R-DHAP or R-DHAP plus Polatuzumab Vedotin as induction treatment plus autologous transplant.

Phase:

Phase 2

Details

Lead Sponsor:

Fondazione Italiana Linfomi - ETS

Collaborator:

Roche Pharma AG